Selenium supplementation in euthyroid patients with thyroid peroxidase antibodies.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22027

Enrollment

150

Registered

2005-05-06

Start date

2005-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Selenium supplementation or placebo.

Eligibility

Inclusion criteria

Inclusion criteria: Thyroid peroxidase antibodies >100 kU/l, TSH 0.4-4.0 mE/L, FT4 10-23 pmol/l, T3 1.30-2.70 nmol/L, female sex.

Exclusion criteria

Exclusion criteria: Use of multivitamin tablets containing selenium in the month preceding inclusion, drug or alcohol abuse, no informed consent.

Design outcomes

Primary

Measure	Time frame
Change of TPO-antibody concentration, difference in TSH level.	—

Secondary

Measure	Time frame
Development of subclinical or overt hypothyroidism and quality of life estimation.	—

Contacts

Public ContactS.A. Eskes

Academic Medical Center (AMC), Department of Endocrinology, P.O. Box 22660

S.A.Eskes@amc.uva.nl+31 (0)20 5669111

Outcome results